Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2021 financial results will be released on Thursday, July 29, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2021 financial results and will provide a business update. A live webcast will be available on the investor relations page of http://investors.gilead.com and will be archived on www

Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021

Altria

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

And there's a good chance you could be earning even more than that.

Investing $72,036 Into These 3 Stocks Can Generate $300 in Monthly Income for Your Portfolio

According to a study published in the Annals of Internal Medicine, neither Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) nor hydroxychloroquine (HCQ) did significantly clear the virus from hospitalized COVID-19 patients or affect the degree of respiratory failure and inflammation over the standard of care after ten days. Between 28 March and 4 October 2020, 185 patients were randomly assigned, and 181 were included in the full analysis set.

Gilead's Remdesivir Fails To Show Antiviral Effects Against COVID-19 In Small WHO Study

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company's upcoming contributions to the 11th International AIDS Society (IAS) Conference on HIV Science, taking place virtually from July 18-21. Thirty-one abstracts reflect Gilead's ongoing commitment to scientific innovation, a key pillar to addressing unmet needs in HIV treatment and prevention. Beyond presenting new scientific data from the company's HIV research and development programs, Gilead w

Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research

In a recent article, we highlighted a list of large-cap, high-quality dividend stocks with the ability to produce stable option income over the next 12 months. This article is part of a series that will individually cover some of our favorite stocks from that list.

Gilead: Great For Covid And Your Income Portfolio

AbbVie

Amgen

Amazon

Alibaba

General Mills

Alphabet

Henkel AG & Co KGaA

Reckitt Benckiser Group PLC

Tencent Holdings Limited

Walgreens

The stock market is overvalued, but we can still try to find investments without overpaying. A first category of stocks are recession-proof and undervalued companies like Walgreens Boots Alliance, Henkel, Amgen or AbbVie.

10 Picks For July

Clorox

Cabot Oil & Gas

Quest Diagnostics

Hologic

Labcorp Holdings Inc

Merck

Pfizer

PerkinElmer

Regeneron Pharmaceuticals

Texas Instruments

The shares of these S&P 500 companies are not only priced right—they also could hold up better during volatility.

11 Quality Stocks That Are Relatively Cheap

Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.

Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?

Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.

Gilead's (GILD) Kite Announces Positive Data on Yescarta

Pardes Biosciences Inc, an early-stage biopharmaceutical company, and FS Development Corp. II (NASDAQ: FSII), a Foresite Capital sponsored SPAC, entered into a definitive merger agreement. Pardes Biosciences was founded at the beginning of 2020 by Uri Lopatin, a former Gilead executive who co-founded and served as CMO of Assembly Biosciences.

Gilead, Foresite Take Pardes Biosciences Public In $250M SPAC Deal

bluebird bio

Bristol-Myers

Johnson & Johnson

Legend Biotech

Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.

Will This 2020 Biotech IPO Crush the Market This Year?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company completed submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection. The submission is supported by data from the Phase 2/3 CAPELLA trial,

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

Gilead Sciences Inc's (NASDAQ: GILD) unit Kite Pharma has announced top-line results from the primary analysis of ZUMA-7 of Yescarta (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line relapsed or refractory large B-cell lymphoma (LBCL). Yescarta boosted event-free survival (EFS) over a standard of care regimen of physicians'-choice therapy followed by high-dose chemo plus a stem cell transplant.

Gilead's Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced top-line results from the primary analysis of ZUMA-7, a randomized Phase 3 global, multicenter study showing superiority of Yescarta® (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line relapsed or refractory large B-cell lymphoma (LBCL). With a median follow-up of two years, the study met the primary endpoint of event-free survival (EFS; hazard ratio 0.398, p

Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma

Big Lots

Boston Scientific

Qurate Retail Inc

Suncor Energy

The following are the best-performing stocks over the past six months that have a long-term presence in more than five gurus' portfolios.

5 Rising Stocks in Gurus' Portfolios

Home Depot

Hormel Foods

JPMorgan Chase & Co

Lockheed Martin

Mastercard

Northern Trust

Starbucks

Charles Schwab

These income stocks boast huge dividend growth rates and should generate large passive income streams over the next decade. The post 10 Best Stocks to Buy to Build Up Passive Income Streams appeared first on InvestorPlace.

10 Best Stocks to Buy to Build Up Passive Income Streams

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from the Phase 2b and Phase 3 clinical trials evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV). Findings from the Phase 3 study support the safety and efficacy profile of bulevirtide 2 mg once daily and are being presented today as a late-breaker in the International Liver Congress™ (ILC) 2021 Official Press Pro

Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks

Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.

Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients

AGNC Investment

Alerian MLP ETF

Cisco Systems

Enbridge

Cheniere Energy

Global X MLP & Energy Infrastructure ETF

Medical Properties Trust

Schwab US Dividend Equity ETF

Starwood Property

AT&T

Cohen & Steers Infrastructure Fund Inc

After 16 weeks and $1,600, the Dividend Harvesting Portfolio is generating $101.61 in estimated annual income and $8.47 in monthly estimated income. I started a position in the Global X MLP & Energy Infrastructure Fund while adding to Starwood Property Trust, AGNC Investment, and AT&T.

Dividend Harvesting: Adversity And Milestones, Week 16 Update

Shares of Gilead Sciences Inc. gained 0.3% in premarket trading on Monday after the drug maker said retrospective research shows that Veklury, its COVID-19 treatment, reduces mortality among people who have been hospitalized with COVID-19. Veklury, which received full approval from the Food and Drug Administration last year, can be prescribed to people who have COVID-19, are hospitalized, and at least 12 years old.

Gilead says real-world data shows COVID-19 drug Veklury can reduce the risk of death

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive data from three retrospective studies of the real-world treatment of patients hospitalized with COVID-19, adding to the body of mortality and hospital discharge data for patients treated with Veklury® (remdesivir). Presented at the World Microbe Forum (WMF) this week, all three of the real-world analyses observed that, in the overall patient populations, patients who received Veklury treatment ha

Gilead's Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that more than 70 abstracts from the company's liver disease programs will be presented at The International Liver Congress™ 2021 (ILC) taking place from June 23-26. The breadth of data reflects Gilead's continued commitment to liver disease, including the recent expansion into chronic hepatitis delta virus (HDV), with Hepcludex® (bulevertide) as the first-in-class treatment for people with HDV conditiona

Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

In the latest trading session, Gilead Sciences (GILD) closed at $67.22, marking a -0.16% move from the previous day.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

News for Gilead Sciences Stock (GILD)